PRRUF News and Press, Immutep Ltd

2024-07-15 13:54:02 ET Summary Immutep Limited achieved positive results in the phase 2b study, using efti + Keytruda for the treatment of patients with 1st-line head and neck squamous cell carcinoma; Both PD-L1 positive and negative patients. Company to meet with FDA to be in a p...

The following slide deck was published by Immutep Limited in conjunction with this event. For further details see: Immutep (IMMP) presents at Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit - Slideshow

The following slide deck was published by Immutep Limited in conjunction with this event. For further details see: Immutep (IMMP) presents TACTI-002 data at ASCO 2022 - Slideshow

The following slide deck was published by Immutep Limited in conjunction with this event. For further details see: Immutep (IMMP) Investor Presentation - Slideshow

Aimmune Gets a Boost as FDA Green Signals Allergy Medication Aimmune Therapeutics ( AIMT ) received FDA nod for its peanut allergy medication Palforzia. This orally administered medication aims to mitigate allergic reactions caused by exposure to peanuts. While it is not designed to be an ...